Pharsight

Application	Filing Date	Opposition Party	Legal Status

EP17175864A	2020-08-13	STADA Arzneimittel AG	Granted and Under Opposition
EP17175864A	2020-08-12	Intas Pharmaceuticals Ltd.	Granted and Under Opposition
EP17175864A	2020-08-10	Generics (U.K.) Limited	Granted and Under Opposition
EP17175864A	2020-08-07	Alfred E. Tiefenbacher (GmbH & Co. KG)	Granted and Under Opposition
EP17175864A	2020-08-07	Wittkopp, Alexander	Granted and Under Opposition
EP17175864A	2020-08-06	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP17175864A	2020-08-06	Kutzenberger Wolff & Partner	Granted and Under Opposition
EP17175864A	2020-08-06	von Seebach, Malte	Granted and Under Opposition
EP17175864A	2020-08-04	Zentiva k.s.	Granted and Under Opposition
EP17175864A	2020-08-04	Teva Pharmaceutical Industries LTD.	Granted and Under Opposition
EP17175864A	2020-08-03	SANDOZ AG	Granted and Under Opposition
EP17175864A	2020-08-03	Krka, d.d., Novo mesto	Granted and Under Opposition
EP17178613A	2020-07-16	Generics (U.K.) Limited	Granted and Under Opposition
EP17178613A	2020-07-16	STADA Arzneimittel AG	Granted and Under Opposition
EP17175788A	2020-07-16	Generics (U.K.) Limited	Granted and Under Opposition
EP17175788A	2020-07-16	STADA Arzneimittel AG	Granted and Under Opposition
EP17178613A	2020-07-15	Intas Pharmaceuticals Ltd.	Granted and Under Opposition
EP17178613A	2020-07-15	KRKA, d.d., Novo mesto	Granted and Under Opposition
EP17178613A	2020-07-15	Sandoz AG	Granted and Under Opposition
EP17175788A	2020-07-15	Intas Pharmaceuticals Ltd.	Granted and Under Opposition
EP17175788A	2020-07-15	KRKA, d.d., Novo mesto	Granted and Under Opposition
EP17175788A	2020-07-15	Sandoz AG	Granted and Under Opposition
EP17178613A	2020-07-14	Medichem S.A.	Granted and Under Opposition
EP17178613A	2020-07-14	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP17175788A	2020-07-14	Medichem S.A.	Granted and Under Opposition
EP17175788A	2020-07-14	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP17178613A	2020-07-13	Kutzenberger Wolff & Partner	Granted and Under Opposition
EP17178613A	2020-07-13	Zentiva k.s.	Granted and Under Opposition
EP17175788A	2020-07-13	Kutzenberger Wolff & Partner	Granted and Under Opposition
EP17175788A	2020-07-10	Zentiva k.s.	Granted and Under Opposition
EP17178613A	2020-07-02	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP17175788A	2020-07-02	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP15190823A	2019-09-05	STADA Arzneimittel AG	Granted and Under Opposition
EP15190823A	2019-09-04	Generics (U.K.) Limited	Granted and Under Opposition
EP15190823A	2019-09-04	Zentiva, k.s.	Granted and Under Opposition
EP15190823A	2019-09-04	Intas Pharmaceuticals Ltd.	Granted and Under Opposition
EP15190823A	2019-09-03	KRKA, d.d., Novo mesto	Granted and Under Opposition
EP15190823A	2019-09-03	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP15190823A	2019-08-30	Hamm&Wittkopp Patentanwälte PartmbB	Granted and Under Opposition
EP15190823A	2019-08-29	Sandoz AG	Granted and Under Opposition
EP15190823A	2019-08-27	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP11707284A	2016-09-16	STADA Arzneimittel AG	Revoked
EP11707284A	2016-09-16	KRKA, d.d., Novo mesto	Revoked
EP11707284A	2016-09-16	Galenicum Health S.L.	Revoked
EP11707284A	2016-09-16	Generics (U.K.) Limited	Revoked
EP11707284A	2016-09-16	Hamm&Wittkopp Patentanwälte PartmbB	Revoked
EP11707284A	2016-09-16	Intas Pharmaceuticals Ltd.	Revoked
EP11707284A	2016-09-16	LEK Pharmaceuticals d.d.	Revoked
EP11707284A	2016-09-16	Zentiva k.s.	Revoked
EP11707284A	2016-09-15	Plougmann Vingtoft a/s	Revoked
EP11707284A	2016-09-15	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Revoked
EP11707284A	2016-09-14	Teva Pharmaceutical Industries Ltd	Revoked

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9326945	April, 2018	Terminated-Settled	Pfizer Inc.	Mylan Pharmaceuticals Inc.
US6967208	August, 2015	Terminated-Denied	Bristol-Myers Squibb Company	Coalition for Affordable Drugs IX, LLC

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6413980	BRISTOL MYERS SQUIBB	Nitrogen containing heterobicycles as factor Xa inhibitors	Dec, 2019 (4 years ago)
US6967208	BRISTOL MYERS SQUIBB	Lactam-containing compounds and derivatives thereof as factor Xa inhibitors	Nov, 2026 (2 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326945	BRISTOL MYERS SQUIBB	Apixaban formulations	Feb, 2031 (6 years from now)

Eliquis is owned by Bristol Myers Squibb.

Eliquis contains Apixaban.

Eliquis has a total of 3 drug patents out of which 1 drug patent has expired.

Expired drug patents of Eliquis are:

US6413980

Eliquis was authorised for market use on 28 December, 2012.

Eliquis is available in tablet;oral dosage forms.

Eliquis can be used as treatment of deep vein thrombosis (dvt), prophylaxis of pulmonary embolism.

Drug patent challenges can be filed against Eliquis from 28 December, 2016.

The generics of Eliquis are possible to be released after 24 February, 2031.

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-690)	Aug 21, 2017
New Indication(I-661)	Aug 21, 2017
New Indication(I-691)	Aug 21, 2017
New Indication(I-681)	Mar 03, 2017
New Chemical Entity Exclusivity(NCE)	Dec 28, 2017

Drugs and Companies using APIXABAN ingredient

NCE-1 date: 28 December, 2016

Market Authorisation Date: 28 December, 2012

Treatment: Treatment of deep vein thrombosis (dvt); Prophylaxis of pulmonary embolism

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2.5MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription

Pharsight

Eliquis patents expiration

ELIQUIS family patents

Related content